Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
1. A method for delivering natalizumab to a patient in need thereof, the method comprising:
swallowing an enclosure having an interior, a delivery means, and a natalizumab preparation coupled to the delivery means, the natalizumab preparation comprising a therapeutically effective dose of natalizumab, the delivery means having a first configuration and a second configuration, the preparation being contained within the interior in the first configuration and advanced out of the interior and into a gastro-intestinal (GI) lumen wall in the second configuration so as to deliver the natalizumab preparation into the GI lumen wall, the enclosure protecting the natalizumab preparation from degradation by GI fluids, the natalizumab preparation supplied in the enclosure in a solid or semi-solid form which can be delivered from the enclosure into the wall of the GI lumen by the application of force on the preparation, wherein the solid or semi-solid form of the natalizumab preparation is shaped as a tissue penetrating member; and
triggering the delivery means responsive to a condition in the GI lumen to deliver the natalizumab preparation from the enclosure into the wall of the GI lumen.
2. The method of claim 1 , wherein the GI lumen is the small intestine.
3. The method of claim 1 , wherein the GI lumen is the stomach.
4. The method of claim 1 , wherein the condition is a selected pH.
5. The method of claim 4 , wherein the pH is above about 7.1.
6. The method of claim 1 , wherein a weight per cent of natalizumab in the preparation is in a range between about 8 to 12%.
7. The method of claim 1 , wherein a dose of natalizumab in the preparation is in a range from about 1 to 5 mg.
8. The method of claim 7 , wherein the dose of natalizumab in the natalizumab preparation is in a range from about 2 to 4 mg.
9. The method of claim 8 , wherein the dose of natalizumab in the natalizumab preparation is about 3 mg.
10. The method of claim 1 , wherein the natalizumab preparation comprises at least one pharmaceutical excipient.
11. The method of claim 10 , wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.
12. The method of claim 1 , further comprising retaining the natalizumab preparation within the GI lumen wall after insertion.
13. The method of claim 12 , wherein retaining comprises anchoring a portion of the natalizumab preparation in GI lumen wall tissue.
14. The method of claim 1 , wherein delivering the natalizumab preparation comprises applying a force to the natalizumab preparation.
15. The method of claim 14 , wherein the natalizumab preparation is advanced completely into the GI lumen wall by such application of force.
16. The method of claim 14 , wherein the natalizumab preparation is advanced through the GI lumen wall by such application of force.
17. The method of claim 14 , wherein the force is a mechanical force applied to a surface of natalizumab preparation.
18. The method of claim 1 , wherein the natalizumab preparation produces a long-term release of the natalizumab up to about 40 days.
19. The method of claim 1 , further comprising:
using the dose of delivered natalizumab to treat an autoimmune disease.
20. The method of claim 19 , wherein the autoimmune disease is multiple sclerosis.
21. The method of claim 20 , wherein the autoimmune disease is Crohn's disease.
22. The method of claim 1 , wherein the tissue penetrating member includes a pointed tip.